Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration

Journal of Neural Transmission

Volumn 104, Issue 1, 1997, Pages 67-75

  Toffa, S ^b   Kunikowska, G M ^a   Zeng, B Y ^a   Jenner, P ^a   Marsden, C D ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

L buthionine sulphoximine (BSO); Nigrostriatal pathway; Oxidative stress; Parkinson's disease; Reduced glutathione (GSH)

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; MAZINDOL; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; LATERAL BRAIN VENTRICLE; MALE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0031025924     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271295     Document Type: Article

References (27)

1. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace elements in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60: 273-281
2. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38-44
3. Gibb WRG, Lees AJ (1988) The relevence of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752
4. Griffith OW (1982) Mechanism of action, metabolism and toxicity of buthionine sulphoximine and its higher homologues, potent inhibitors of elutathione synthesis. J Biol Chem 257: 13704-13712
5. Griffith OW, Meister A (1985) Origin and turnover of mitochondrial glutathione. PNAS 82: 4668-4672
6. Jain A, Martensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. PNAS 88: 1913-1917
7. 3H]-maxindol autoradiography. J Neurosci 5: 1513-1521
8. Jellinger K (1987) The pathology of parkinsonism, 1st edn. Movement disorders 2. Butterworths, London, pp 125-130
9. Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
10. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 3: 876-881
11. Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis and its reversal: applications in research and therapy. Pharmacol Ther 51: 155-194
12. Paxinos G, Watson C (1986) The rat brain in stereotaxic co-ordinates, 2nd edn. Academic Press, San Diego
13. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) Stereotaxic atlas of the rat brain, 2nd edn. Plenum Press, New York
14. Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310
15. Pileblad E, Magnusson T (1989) Intracerebrovetricular administration of L-buthionine sulfoximine: a method for depleting brain glutathione. J Neurochem 53: 1878-1882
16. Pileblad E, Magnusson T, Fornstedt B (1989) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52: 978-980
17. Reed DJ, Babson JR, Beatty PW, Brodie AE, ElHs WW, Potter DW (1980) High performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulphide, and related thiols and disulphides. Anal Biochem 106: 55-62
18. Riederer P, Sofie E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1988) Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
19. Schapira AHV (1994) Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 9: 125-138
20. Seaton TA, Jenner P, Marsden CD (1996) Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm 103: 315-329
21. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994a) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355
22. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994b) Glutathione-related enzymes in Parkinson's disease. Ann Neurol 36: 356-361
23. Sofic E, Paulus W, Jellinger P, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978-982
24. + toxicity. J Neurol [Suppl 2] 242: 571
25. + toxicity in nigral dopaminergic neurones. NeuroReport 7: 921-923
26. Youdim MBH, Ben Schahar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in increased iron and melanin induced neurodegeneration? Acta Neurol Scand 126: 47-54
27. Zarow C, Chui HC (1991) A simple method for assessing neuronal number in the human substantia nigra. Soc Neurosci Abstr 17: 574.10